Innovation Pharmaceuticals Inc (IPIX)

[Empiricst1]

"Probably for years.."

I'm somewhat more optimistic. Alfasigma can get underway in early 2022 and get through the Ph2b shortly thereafter. Unless it runs its testing for a year as one of the BPs has done in IBD. Leo could pull a coup and get some licensing for B for MRSA (the standard IPIX IV limitation would be no limitation here). Or B for OM, how much do you trust Leo on this one? Maybe an anti-viral use of B could pop up strong from the ongoing invitro studies. Or Leo/company could just continue to burn over a million annually on salaries. Of course comment might just be right.